PF-3882845
Names
Biological Activity
[Description]:
PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC50=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to progesterone receptor (PR) with the binding IC50 of 310 nM[1].
[Related Catalog]:
[Target]
IC50: 2.7 nM (mineralocorticoid receptor), 310 nM (progesterone receptor)[1]
[In Vivo]
PF-3882845 reduces blood pressure, decreases urinary albumin, and protects kidney in Dahl SS rat[1]. PF-3882845 exhibits moderate oral bioavailability (F 86%) following oral administration (2 mg/kg) in male Sprague-Dawley rats[1]. PF-3882845 exhibits terminal elimination half-lives (T1/2 1.7 h) due to high plasma clearance (CL 9.8 mL/min/kg) combined with large volumes of distribution (Vdss 1.4 mL/kg respectively) following intravenous administration (2 mg/kg) in male Sprague-Dawley rats[1]. Animal Model: Male Dahl salt sensitive (SS) rats[1] Dosage: 10, 40, and 100 mg/kg Administration: Orally via gavage; twice a day; for 21 days Result: Significant blood pressure reduction was observed with 10 mg/kg. Most noticeably, rats dosed at 40 and 100 mg/kg had negligible increase in blood pressure over 21 days in the presence of high salt.
[References]
Chemical & Physical Properties
[ Molecular Formula ]:
C24H22ClN3O2
[ Molecular Weight ]:
419.90300
[ Exact Mass ]:
419.14000
[ PSA ]:
76.69000
[ LogP ]:
4.75598
MSDS
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H315-H319-H335
[ Precautionary Statements ]:
P261-P305 + P351 + P338
[ RIDADR ]:
NONH for all modes of transport